Drug updated on 5/1/2024
| Dosage Form | Injection (intravenous; 200 mg/2 mL, 500 mg/5 mL) |
| Drug Class | Modified gamma cyclodextrins |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.
Summary
- Sugammadex (Bridion) is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.
- A total of 23 systematic reviews/meta-analyses were reviewed to gather information about this drug's safety, effectiveness, comparison with other drugs like neostigmine, as well as its use in various population subgroups including pediatric patients.
- In terms of safety profile, sugammadex (Bridion) demonstrated a more favorable outcome compared to traditional regimens or placebos when used on children for reversing rocuronium-induced neuromuscular blockade; it had lower incidence rates of adverse effects.
- There exists a rare but significant risk associated with sugammadex (Bridion), namely anaphylaxis which has been observed at incidence rates between 0.02% -0.04%, warranting further investigation despite these low occurrence rates.
- Patients suffering from systemic mastocytosis can safely be administered sugammadex (Bridion), confirmed through tryptase level monitoring.
- Compared against neostigmine, multiple studies have shown that using sugammadex (Bridion) results in lower risks related postoperative residual neuromuscular blockade and pulmonary complications such pneumonia or respiratory failure; it also showed reduced instances bradycardia along with postoperative nausea/vomiting.
- Sugammadex(Bridon)'s efficacy was highlighted across adult/pediatric populations where it consistently outperformed traditional acetylcholinesterase inhibitors/neostigmine both speed/efficacy wise while reversing moderate/deep blocks thus reducing risk residual block/associated pulmonary complications.
- In specific surgical contexts like colorectal surgery, sugammadex (Bridion) has shown to significantly enhance gastrointestinal motility postoperatively compared to acetylcholinesterase inhibitors; however its impact on surgical morbidity and hospital stay length remains similar between the groups.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Bridion (sugammadex) Prescribing Information. | 2022 | Merck Sharp & Dohme LLC., Rahway, NJ |